Guggenheim Maintains Buy on Sagimet Biosciences, Raises Price Target to $26

Benzinga · 3d ago
Guggenheim analyst Seamus Fernandez maintains Sagimet Biosciences (NASDAQ:SGMT) with a Buy and raises the price target from $25 to $26.